NASDAQ · OLK
Healthcare · Medical - Diagnostics & Research
$26.08
Up+$0.08 (+0.31%)
Updated Sep 12, 2026, 2:29 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
OLK does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning OLK.
OLK research
Company profile and research snapshot.
Olink Holding AB (publ) provides various products and services for the academic, government, biopharmaceutical, biotechnology, and other institutions that focuses on life science research. Its products include Olink Explore for cardiovascular and metabolic, oncology, neurology, or inflammation diseases; Olink Target product line; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. The company's products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and bioinformatics services. In addition, it provides Olink normalized protein expression (NPX) Manager, a purpose-built software that enable users to import data, validate data quality, and normalize for subsequent statistical analysis; and Olink Insight, a cloud platform for data visualization and statistical analysis of NPX data. Olink Holding AB (publ) sells its products and services through its own direct sales force in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. The company was founded in 2004 and is headquartered in Uppsala, Sweden. Olink Holding AB (publ) is a subsidiary of Summa Equity Holding AB.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 26, 2024 | Morgan Stanley | Equal-Weight | — |
| Mar 26, 2024 | Canaccord Genuity | Hold | — |
| Oct 24, 2023 | Morgan Stanley | Equal-Weight | — |
| Oct 18, 2023 | Scotiabank | Sector Perform | — |
| Aug 10, 2023 | Morgan Stanley | Equal-Weight | — |
No generated briefing is available yet.
Investing.com · Jul 8, 2024
The UK's competition regulator has cleared Thermo Fisher Scientific's $3.1 billion acquisition of Swedish biotech firm Olink Holding.
GlobeNewswire Inc. · Jul 5, 2024
Olink Holding AB held an Extra General Meeting and resolved to grant each board member additional compensation over a number of years, totaling USD 127,504.
GlobeNewswire Inc. · Jun 11, 2024
This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail.
GlobeNewswire Inc. · Jun 6, 2024
UPPSALA, Sweden, June 06, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a detailed view of the immune system for in-depth monitoring of inflammation and immune response in clinical research.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OLK.
No results
No recent SID articles mention OLK.
